DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions

Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways.

"We are very excited to receive this patent, which covers key innovations in the use of blood volume analysis to optimally guide fluid treatment,” said Jonathan Feldschuh, Chief Scientific Officer of Daxor. “Modern medicine demands smarter systems with AI and advanced guidance to optimize care; this patent broadly protects Daxor’s leading technology for the use of smart blood volume systems to achieve optimal outcomes. We are actively developing hardware and software solutions embodying these patented concepts—with the support of the National Institutes of Health—to help all clinicians achieve the kind of improved outcomes demonstrated by experts using blood-volume-guided treatment for conditions such as heart failure and trauma."

“This patent award is a significant milestone for our company,” said Michael Feldschuh, CEO and President of Daxor. “Our mission at Daxor is to advance healthcare by enabling optimal fluid management, providing physicians the tools to diagnose and treat more effectively. Our proprietary technology, protected by multiple patents, provides a competitive advantage as we bring next-generation products to market that accomplish this mission. This patent represents the first of over half a dozen patents pending for which the company looks forward to receiving favorable decisions from the U.S. Patent Office.”

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com